Phase I Multiple Ascending Dose study for AZD 7268 in Healthy Volunteers

Study identifier:D1151C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Healthy Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7268, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Apr 2009

Primary Completion Date: -

Study Completion Date: 01 Oct 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Philadelphia, PA, United States

Arms	Assigned Interventions
Experimental: AZD7268	Drug: AZD7268 Capsule, Oral, QD Drug: AZD7268 Capsule, Oral, BID
Placebo Comparator: Placebo	Drug: Placebo Capsule, Oral BID Drug: Placebo Capsule, Oral BID

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1738&filename=CSR-D1151C00003.pdf
Download
CSR-D1151C00003.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Sylvan Hurewitz

AstraZeneca Clinical Pharmacology Unit, US